We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The buzz at the Drug Information Association’s (DIA) annual meeting — being held in person this week in Chicago after two “virtual” years — is focused largely on user fee reauthorization as a legislative package makes its way through the Senate following the passage of a House version on June 8. Read More
The FDA has issued a warning letter to Hybrid Pharma — a Deerfield Beach, Fla.-based compounder — for producing adulterated drugs and failing to have any approved applications on file for the products. Read More
With positive new phase 3 interim results in hand, AstraZeneca is poised to file for regulatory approval for eplontersen, an antisense drug to treat complications of transthyretin amyloidosis (ATTR), a rare and fatal disease. Read More
If millionaire entrepreneur and television personality Mark Cuban’s online generic drug company had existed in 2020, it would have saved Medicare Part D as much as $3.6 billion, or 37 percent of the $9.6 billion spent that year on 77 of 89 different prescription drugs. Read More